TLC BioSciences Announces Publication of TLC599 Phase II Results in Arthritis Research & Therapy

SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, March 07, 2022 (GLOBE NEWSWIRE) -- TLC BioSciences, a clinical-stage specialty pharmaceutical company developing novel nanomedicines to target areas of unmet medical need, today announced that detailed results of its TLC599 Phase 2 clinical trial in patients with osteoarthritis of the knee have been published in the peer-reviewed journal Arthritis Research & Therapy. TLC599 is a proprietary BioSeizer^® sustained release formulation of dexamethasone sodium phosphate (DSP) intended for the treatment of osteoarthritis pain. The results demonstrated statistically significantly reduced pain scores and oral pain medication use for up to 6 months with TLC599.

Read more at globenewswire.com